Contrave 8 mg/90 mg Prolonged-release tablet.
PDF Leaflet Revision Date: 25 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of weight in adults with obesity or overweight with comorbidities.
Dosage (summary)
Initial dose escalated over 4 weeks; max 32 mg naltrexone/360 mg bupropion daily.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to unknown risks.
Key Drug Interactions
- Monoamine oxidase inhibitors (MAOI)
- Opioid analgesics
- CYP2D6 substrates
Contraindications
- Hypersensitivity
- Uncontrolled hypertension
- Seizure disorder
- CNS tumors
- Acute alcohol withdrawal
- Bipolar disorder
- Eating disorders
- Chronic opioid dependence
Common side effects
- Nausea
- Constipation
- Dizziness
- Dry mouth
- Headache
Counselling Points
- Monitor for mood changes or suicidal thoughts.
- Avoid alcohol consumption.
- Take with food to enhance absorption.
Serious warnings
- Risk of seizures
- Suicidal behavior
- Increased blood pressure
- Hepatotoxicity
Important Disclaimer
The Contrave 8 mg/90 mg Prolonged-release tablet. professional information leaflet below is the property of Acino Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
